These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 23293303)

  • 21. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
    Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
    J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of decreased peripheral congestion detected by Bioelectrical Impedance Vector Analysis (BIVA) in patients hospitalized for acute heart failure: BIVA prognostic value in acute heart failure.
    Santarelli S; Russo V; Lalle I; De Berardinis B; Vetrone F; Magrini L; Di Stasio E; Piccoli A; Codognotto M; Mion MM; Castello LM; Avanzi GC; Di Somma S;
    Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):339-347. PubMed ID: 27073131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).
    Ambrosy AP; Bhatt AS; Gallup D; Anstrom KJ; Butler J; DeVore AD; Felker GM; Fudim M; Greene SJ; Hernandez AF; Kelly JP; Samsky MD; Mentz RJ
    Am J Cardiol; 2017 Jul; 120(1):98-105. PubMed ID: 28479167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
    Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
    Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
    Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
    Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge.
    Hogenhuis J; Voors AA; Jaarsma T; Hillege HL; Hoes AW; van Veldhuisen DJ
    Am Heart J; 2006 May; 151(5):1012.e1-5. PubMed ID: 16644323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
    Wang NC; Maggioni AP; Konstam MA; Zannad F; Krasa HB; Burnett JC; Grinfeld L; Swedberg K; Udelson JE; Cook T; Traver B; Zimmer C; Orlandi C; Gheorghiade M;
    JAMA; 2008 Jun; 299(22):2656-66. PubMed ID: 18544725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
    Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F
    Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.
    Bettencourt P; Azevedo A; Pimenta J; Friões F; Ferreira S; Ferreira A
    Circulation; 2004 Oct; 110(15):2168-74. PubMed ID: 15451800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure.
    Cobo Marcos M; Comín-Colet J; de la Espriella R; Rubio Gracia J; Morales-Rull JL; Zegrí I; Llacer P; Diez-Villanueva P; Jiménez-Marrero S; de Juan Bagudá J; Ortiz Cortés C; Goirigolzarri-Artaza J; García-Pinilla JM; Barrios E; Del Prado Díaz S; Montero Hernández E; Sanchez-Marteles M; Nuñez J
    ESC Heart Fail; 2024 Jun; 11(3):1767-1776. PubMed ID: 38380837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal function trajectories and clinical outcomes in acute heart failure.
    Givertz MM; Postmus D; Hillege HL; Mansoor GA; Massie BM; Davison BA; Ponikowski P; Metra M; Teerlink JR; Cleland JG; Dittrich HC; O'Connor CM; Cotter G; Voors AA
    Circ Heart Fail; 2014 Jan; 7(1):59-67. PubMed ID: 24281137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
    Gheorghiade M; Pang PS; Ambrosy AP; Lan G; Schmidt P; Filippatos G; Konstam M; Swedberg K; Cook T; Traver B; Maggioni A; Burnett J; Grinfeld L; Udelson J; Zannad F
    Heart Fail Rev; 2012 May; 17(3):485-509. PubMed ID: 21932146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction.
    Wang NC; Piccini JP; Konstam MA; Maggioni AP; Traver B; Swedberg K; Udelson JE; Zannad F; Cook T; O'Connor CM; Miller AB; Grinfeld L; Gheorghiade M;
    Am J Ther; 2010; 17(4):e78-87. PubMed ID: 20634650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.
    Ambrosy AP; Cerbin LP; Armstrong PW; Butler J; Coles A; DeVore AD; Dunlap ME; Ezekowitz JA; Felker GM; Fudim M; Greene SJ; Hernandez AF; O'Connor CM; Schulte P; Starling RC; Teerlink JR; Voors AA; Mentz RJ
    JACC Heart Fail; 2017 Jan; 5(1):1-13. PubMed ID: 28034373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).
    Fudim M; Parikh KS; Dunning A; DeVore AD; Mentz RJ; Schulte PJ; Armstrong PW; Ezekowitz JA; Tang WHW; McMurray JJV; Voors AA; Drazner MH; O'Connor CM; Hernandez AF; Patel CB
    Am J Cardiol; 2018 Nov; 122(9):1506-1512. PubMed ID: 30172362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.